drugset / Trial / NCT02622243

Duration of Long Acting Muscarinic Antagonist (LAMA) Bronchoprotection Against Methacholine Challenge

NCT02622243

Phase 4 Completed 13 enrolled University of Saskatchewan
RandomizedCrossoverTriple-blindTreatment

Summary

The study will assess the duration of protection of single doses of 2 different long acting muscarinic antagonists against methacholine induced bronchoconstriction.

Timeline

Start
2015-11
Primary completion
2016-03
Completion
2016-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Glycopyrronium Unknown 50 ug Inhaled
Subject Tiotropium Other / unclassified 5 ug Inhaled

Indications